Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020
Dublin Core | PKP Metadata Items | Metadata for this Document | |
1. | Title | Title of document | Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020 |
2. | Creator | Author's name, affiliation, country | Natalia Yu. Pshenichnaya; National Medical Research Center of Tuberculosis and Infectious Diseases; Central Research Institute of Epidemiology; Russian Federation |
2. | Creator | Author's name, affiliation, country | Elena N. Kareva; Sechenov First Moscow State Medical University (Sechenov University); Pirogov Russian National Research Medical University; Russian Federation |
2. | Creator | Author's name, affiliation, country | Irina A. Leneva; Mechnikov Research Institute of Vaccines and Serums; Russian Federation |
2. | Creator | Author's name, affiliation, country | Vilya A. Bulgakova; Pirogov Russian National Research Medical University; Central Clinical Hospital; Russian Federation |
2. | Creator | Author's name, affiliation, country | Irina E. Kravchenko; Kazan State Medical University; Russian Federation |
2. | Creator | Author's name, affiliation, country | Irina V. Nikolaeva; Kazan State Medical University; Russian Federation |
2. | Creator | Author's name, affiliation, country | Antonina I. Grekova; Smolensk State Medical University; Russian Federation |
2. | Creator | Author's name, affiliation, country | Antonina P. Ivanova; Kursk State Medical University; Russian Federation |
2. | Creator | Author's name, affiliation, country | Larisa V. Puzyreva; Omsk State Medical University; Russian Federation |
2. | Creator | Author's name, affiliation, country | Guzel M. Khasanova; Bashkir State Medical University; Russian Federation |
2. | Creator | Author's name, affiliation, country | Svetlana N. Orlova; Ivanovo State Medical Academy; Russian Federation |
2. | Creator | Author's name, affiliation, country | Elena P. Tikhonova; Voino-Yasenetsky Krasnoyarsk State Medical University; Russian Federation |
2. | Creator | Author's name, affiliation, country | Vladimir A. Petrov; Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology; Obninsk Institute for Nuclear Power Engineering; Russian Federation |
2. | Creator | Author's name, affiliation, country | Oleg V. Malinin; Izhevsk State Medical Academy; Russian Federation |
2. | Creator | Author's name, affiliation, country | Natalia V. Kolaeva; Sechenov First Moscow State Medical University (Sechenov University); Russian Federation |
2. | Creator | Author's name, affiliation, country | Elena V. Volchkova; Sechenov First Moscow State Medical University (Sechenov University); Russian Federation |
2. | Creator | Author's name, affiliation, country | Nina N. Kanshina; Sechenov First Moscow State Medical University (Sechenov University); Russian Federation |
2. | Creator | Author's name, affiliation, country | Vladimir P. Chulanov; National Medical Research Center of Tuberculosis and Infectious Diseases; Sechenov First Moscow State Medical University (Sechenov University); Russian Federation |
3. | Subject | Discipline(s) | |
3. | Subject | Keyword(s) | coronaviruses; SARS-CoV-2; COVID-19; antiviral therapy; umifenovir; lopinavir; ritonavir; hydroxychloroquine; interferon |
4. | Description | Abstract | Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age – 48.7±18.1 (median – 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median – 54 vs 21 years; p<0.001), higher body mass index (27.8 vs 23.4; p<0.001), prevalence of chronic diseases (75.3% vs 8.5%; p<0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.8±6.1 vs 4.2±2.7 days; p<0.001) and catarrhal symptoms duration (10.2±5.4 vs 6.1±4.1 days; p<0.001). Results. During hospitalization 92% of the patients received AVT, 77% – antibiotics, and 16% – corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.7±5.5 vs 11.7±5.5 days; p<0.001) and catarrhal symptoms duration (8.8±5.1 vs 12.0±4.9 days; p<0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.9±7.5 vs 11.7±5.5; p<0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics. Conclusion. Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients. |
5. | Publisher | Organizing agency, location | LLC Obyedinennaya Redaktsiya |
6. | Contributor | Sponsor(s) | |
7. | Date | (DD-MM-YYYY) | 15.11.2021 |
8. | Type | Status & genre | Peer-reviewed Article |
8. | Type | Type | Research Article |
9. | Format | File format | |
10. | Identifier | Uniform Resource Identifier | https://ter-arkhiv.ru/0040-3660/article/view/99553 |
10. | Identifier | Digital Object Identifier (DOI) | 10.26442/00403660.2021.11.201206 |
11. | Source | Title; vol., no. (year) | Terapevticheskii arkhiv; Vol 93, No 11 (2021) |
12. | Language | English=en | ru |
13. | Relation | Supp. Files |
Fig. 1. COVID-19 cases in the Russian Federation during the study period (black line) and the number of patients included in the study. (85KB) |
14. | Coverage | Geo-spatial location, chronological period, research sample (gender, age, etc.) | |
15. | Rights | Copyright and permissions |
Copyright (c) 2021 Consilium Medicum![]() This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. |